RxDoctor Payments Data

Jacquelyn Lacera, MD

Family Medicine · Corona, CANPI 1063499200

Payments from drug & device makers

$801in general payments, 2019–2025

Across 38 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$175
  • Gilead$121
  • Johnson & Johnson$89
  • Lilly USA, LLC$84
  • Astellas Pharma US Inc$56
  • GSK$51
  • plus $225 from 9 others

What the payments were for

  • Food & beverage$801100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$801 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$21,155
Medicare patients
60
Services billed
269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$46,294
RybelsusSemaglutide17$35,968
FarxigaDapagliflozin Propanediol19$21,989
JardianceEmpagliflozin11$13,061
OzempicSemaglutide13$11,408
LinzessLinaclotide16$11,255
JanuviaSitagliptin Phosphate11$10,347
Ezetimibe-SimvastatinEzetimibe/Simvastatin67$7,915
Benazepril-HydrochlorothiazideBenazepril/Hydrochlorothiazide115$6,510
Rosuvastatin Calcium236$3,284
Metformin Hcl325$3,052
Levothyroxine Sodium150$2,397
Atorvastatin Calcium175$2,142
Tolterodine Tartrate ErTolterodine Tartrate16$2,140
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide99$1,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$175$47,37630 claims
PfizerEliquis$13$46,29448 claims
AstraZenecaFarxiga$39$21,98919 claims
AbbVieLinzess$16$11,25516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →